Tifcemalimab is under clinical development by Shanghai Junshi Biomedical Technology and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase I drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tifcemalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tifcemalimab is under development for the treatment of recurrent/refractory malignant lymphoma, hodgkin lymphoma (b-cell hodgkin lymphoma), non-hodgkin lymphoma including follicular lymphoma, solid tumors including non-small cell lung cancer, melanoma, Hodgkin lymphoma, urothelial carcinoma, renal cell carcinoma, recurrent or metastatic head and neck squamous cell carcinoma, squamous non-small cell lung carcinoma, non-small cell lung carcinoma, small cell lung cancer and nasopharyngeal carcinoma. It is a monoclonal antibody which is administered through intravenous route. It acts by targeting BTLA (B- and T-lymphocyte attenuator).
Shanghai Junshi Biomedical Technology overview
Shanghai Junshi Biomedical Technology, formerly Shanghai Junshi Bioscience Co Ltd is a biopharmaceutical company that discovers, develops and commercializes drugs for infectious diseases, oncology, metabolic, auto-immunity and neurologic indications. It is investigating JS001 antibody against various malignant tumors; JS003, JS006, and JS201 to treat solid tumors; JS004 for melanoma, hodgkin lymphoma and lung carcinoma; JS101 for the treatment of breast cancer; JS108 for pancreatic, triple negative breast cancer, small cell lung cancer. The company is also evaluates JS002 against hyperlipidaemia; JS103 for hyperuricacidemia and gout disease; UPB1211 to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS010 for migraine; and JS016 against COVID-19. It operates with research and development centers in California and Maryland, the US. Junshi Bioscience is headquartered in Shanghai, China.
For a complete picture of Tifcemalimab’s drug-specific PTSR and LoA scores, buy the report here.